EarlyTect (R) is the promise of Genomictree to keep your tomorrow healthy through early detection of cancer.

Colorectal cancer (CRC) screening can effectively reduce disease-related mortality by detecting CRC at earlier stages. Therefore, early detection of CRC has emerged as an important global issue to reduce its high mortality. Currently, colonoscopy is the most accurate screening method for early diagnosis of CRC. However, its compliance rate remains very low due to its invasiveness, dietary restriction requirement, and extensive bowel preparation. Although noninvasive fecal immunochemical tests (FIT) for hemoglobin in stool are available, their sensitivities are relatively low in detecting stage I CRC. Thus, developing highly accurate CRC screening method using molecular biomarkers for people who are reluctant to participate in colonoscopy examination is urgently needed for early detection of CRC.

Higi Medical Costs

  • 암사망률2위

    Cancer Mortality Rate
    ranked “Second”
    in the World

  • 말기

    About 60% of Patients
    are Detected at
    “Late Stage”

  • 환자 당 평균 치료비용

    Average Treatment Cost
    per patient : Up to USD 150,000 (US),
    up to USD 30,000 (South Korea)


Survival Rate & Treatment Cost


Current Screening Tools for CRC Early Detection

  • Colonoscopy (Gold Standard)
    Colonoscopy (Gold Standard)
    1. High Invasiveness, Inconveniences
    2. Low participation rate due to bowel preparation
      (Worldwide average of less than 30%)
  • FOBT / FIT
    FOBT / FIT
    1. Low sensitivity to early CRC (less than 50%)
      and polyps (≥ 1.0 cm; less than 20%)

Still… “High CRC Incidence Rate & High Mortality Rate”

Unmet Needs

Increase in Participation Rate of Colonoscopy Screening
Increase in Early CRC Detection
근거중심 암 조기진단Evidence-based CRC Early Detection CRC In Vitro Early Detection Technology utilizing Biomarkers
체외진단용 의료기기

This test is a real-time PCR test that measures methylated syndecan-2 (SDC2) DNA using human fecal. Abnormal methylation of the syndecan-2 biomarker in colorectal cancer tissues is observed more than 95% regardless of the stage and is not observed in normal colorectal tissues. This indicates that the presence of methylated syndecan-2 DNA has a significant association with the incidence of colorectal neoplasia. It has been proven to be able to diagnose colorectal cancer with 90% sensitivity and 90% specificity, and 89% sensitivity for early stages (0-II) in a pivotal trial on 585 subjects at Yonsei University Severance Hospital and Severance Check-up Center.

Click here to go the site for EarlyTect® Colon Cancer Test 제품사이트 바로가기